Lidocaine 2 — Class II drug recall D-0794-2022
Terminated recall by Teva Pharmaceuticals USA Inc, reported 2022-05-04, distributed nationwide. cGMP Deviations
| Recall number | D-0794-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA Inc, Parsippany, NJ, United States |
| Recall initiated | 2022-04-15 |
| Classified | 2022-04-27 |
| Reported by FDA | 2022-05-04 |
| Terminated | 2023-05-25 |
| Distributed | Nationwide (US) |
| Quantity | 353,964 units |
| Reason classes | cgmp |
| NDC | 00591-2070-30, 00591-2070-72 |
| Expiration dates | 2022-11, 2022-12, 2024-01, 2024-02, 2024-03, 2024-04 |
Product
Lidocaine 2.5% and Prilocaine 2.5% Cream, USP, packaged in a) 5 g tubes (NDC 0591-2070-72), b) 30 g tubes (NDC 0591-2070-30), Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA
Reason for recall
cGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0794-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.